Studying Rarity in Bladder Cancer

Eur Urol. 2020 Apr;77(4):447-448. doi: 10.1016/j.eururo.2019.11.018. Epub 2019 Dec 5.

Authors

Constance Thibault¹, Pernelle Lavaud², Yohann Loriot³

Affiliations

¹ Medical Oncology Department, Georges Pompidou Hospital, APHP.5, Paris, France.
² Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
³ Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, Université Paris-Sud, Université Paris-Saclay, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.

PMID: 31812317
DOI: 10.1016/j.eururo.2019.11.018

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized
Humans
Neoadjuvant Therapy
Urinary Bladder Neoplasms*

Substances

Antibodies, Monoclonal, Humanized
pembrolizumab